On November 19, Ultragenyx Pharmaceutical rose 5.03% in Regular Trading, trading at $17.56 with turnover of $38.32 million.
The move aligned with recent company updates indicating it will participate in a London investor meeting, while the UK MHRA has accepted the marketing application for UX111 for Sanfilippo syndrome type A, helping improve near-term market sentiment.
Background context shows UX111 has entered the UK regulatory review process, a meaningful milestone for one of Ultragenyx Pharmaceutical’s rare-disease gene therapy candidates. Earlier analyst actions also reflected a constructive longer-term view: RBC Capital raised its price target to $40 from $35 while maintaining Outperform, and Wedbush lifted its target to $30 from $26 while keeping a Neutral rating.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)